| CAS NO: | 92321-29-4 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| Cas No. | 92321-29-4 |
| 别名 | 1-(1-甲基-1-苯基乙基)哌啶 |
| 化学名 | 1-(1-methyl-1-phenylethyl)-piperidine |
| Canonical SMILES | CC(C1=CC=CC=C1)(C)N2CCCCC2 |
| 分子式 | C14H21N |
| 分子量 | 203.3 |
| 溶解度 | ≤30mg/ml in ethanol;30mg/ml in DMSO;30mg/ml in dimethyl formamide |
| 储存条件 | Store at -20℃ |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | KI: 11 microM for 7-(benzyloxy)resorufin O-dealkylation activity of liver microsomes obtained from phenobarbital-induced rats 2-Phenyl-2-(1-piperidinyl)propane is a mechanism-based inactivator of human cytochrome P450 (CYP) 2B6. The use of selective chemical inhibitors of human cytochrome P450 enzymes is a powerful method by which the relative contributions of different human P450 enzymes to the drug metabolism can be obtained. However, the contribution of CYP2B6 in the metabolism is more challenging due to the lack of a well-established inhibitor. In vitro: Previous study found that 2-phenyl-2-(1-piperidinyl)propane could inactivate the 7-(benzyloxy)resorufin O-dealkylation activity of liver microsomes obtained from phenobarbital-induced rats. The 7-ethoxy-4-(trifluoromethyl)coumarin O-deethylation activity of purified rat liver P450 2B1 and expressed human P450 2B6 was also inactivated by 2-phenyl-2-(1-piperidinyl)propane in a reconstituted system. With NADPH, the loss of activity was founf to be both time- and concentration-dependent, and followed pseudo first order kinetics. The time for 50% of the P450 2B1 to become inactivated at saturating concentrations of 2-phenyl-2-(1-piperidinyl)propane was ~2.5 min. P450 2B6 was inactivated by 2-phenyl-2-(1-piperidinyl)propane with a k(inact) of 0.07 min(-1), a K(I) of 1.2 microM, and a t(1/2) of 9.5 min. The inactivated P450s 2B1 and 2B6 lost about 25 and 15%, respectively, indicating that the loss of activity was caused by a 2-phenyl-2-(1-piperidinyl)propane modification of the apoprotein rather than the heme [1]. In vivo: Up to now, there is no animal in vivo data reported. Clinical trial: So far, no clinical study has been conducted. Reference: |
m.cnreagent.com